Biomaterials:缺氧缓解引发增强的光动力疗法与IDO抑制剂联合用于癌症治疗

2019-04-27 不详 网络

光动力疗法(PDT)由于其非侵入性干预和通过使用无毒光敏剂(PS)和局部光照射引发抗肿瘤免疫应答而在癌症治疗领域引起了越来越多的关注。然而,由肿瘤中的检查点介导的固有缺氧和免疫抑制分别损害PDT和PDT诱导的免疫的功效。本文中,研究人员预先通过用氧饱和的氟化聚合物纳米颗粒合理地构建多功能纳米平台,其同时包封PS(Ce6)和吲哚胺2,3-双加氧酶(IDO)抑制剂(NLG919)。特别是,与烷基化聚合

光动力疗法(PDT)由于其非侵入性干预和通过使用无毒光敏剂(PS)和局部光照射引发抗肿瘤免疫应答而在癌症治疗领域引起了越来越多的关注。然而,由肿瘤中的检查点介导的固有缺氧和免疫抑制分别损害PDT和PDT诱导的免疫的功效。

本文中,研究人员预先通过用氧饱和的氟化聚合物纳米颗粒合理地构建多功能纳米平台,其同时包封PS(Ce6)和吲哚胺2,3-双加氧酶(IDO)抑制剂(NLG919)。特别是,与烷基化聚合物纳米粒子作为体外和体内对照相比,肿瘤缺氧微环境明显减轻,氟化纳米粒子产生更多活性氧(ROS),这主要是因为氟化聚合物具有高氧含量携带能力也有助于缓解缺氧。同时,与单独的PDT相比,IDO抑制剂和PS的共包封可以通过增强的T细胞浸润进一步大大增强抑制原发性和远隔性肿瘤生长的功效。

总之,该研究可以为增强PDT的治疗效果和减轻免疫抑制提供方便实用的策略,从而为癌症治疗提供临床益处。

原始出处:

Xing L, Gong JH, et al., Hypoxia alleviation-triggered enhanced photodynamic therapy in combination with IDO inhibitor for preferable cancer therapy. Biomaterials. 2019 Mar 22;206:170-182. doi: 10.1016/j.biomaterials.2019.03.027. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-08-22 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2019-05-21 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]
    2020-03-24 tongyongming
  7. [GetPortalCommentsPageByObjectIdResponse(id=1844282, encodeId=20321844282c4, content=<a href='/topic/show?id=06a2e1405a8' target=_blank style='color:#2F92EE;'>#癌症治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71405, encryptionId=06a2e1405a8, topicName=癌症治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Mon Jul 15 04:44:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851981, encodeId=038a1851981a4, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Aug 22 13:44:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050040, encodeId=3f2e205004085, content=<a href='/topic/show?id=cbdd3451e3' target=_blank style='color:#2F92EE;'>#Biomaterials#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3451, encryptionId=cbdd3451e3, topicName=Biomaterials)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8e0333, createdName=zhangyxzsh, createdTime=Mon Aug 26 06:44:00 CST 2019, time=2019-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715770, encodeId=01491e15770da, content=<a href='/topic/show?id=9517942978' target=_blank style='color:#2F92EE;'>#IDO抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9429, encryptionId=9517942978, topicName=IDO抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1ea832038829, createdName=bshuang, createdTime=Wed Jun 12 11:44:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918642, encodeId=82e61918642c6, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue May 21 16:44:00 CST 2019, time=2019-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703524, encodeId=c4b81e03524dd, content=<a href='/topic/show?id=327e9425fc' target=_blank style='color:#2F92EE;'>#IDO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9425, encryptionId=327e9425fc, topicName=IDO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3e3a30514791, createdName=tongyongming, createdTime=Tue Mar 24 09:44:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546321, encodeId=c2a515463211b, content=<a href='/topic/show?id=0da528e33ce' target=_blank style='color:#2F92EE;'>#光动力#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28733, encryptionId=0da528e33ce, topicName=光动力)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b6213920685, createdName=luckyshitiancai_42705688, createdTime=Mon Apr 29 09:44:00 CST 2019, time=2019-04-29, status=1, ipAttribution=)]